Sign in

    Gabrielle Zhou

    Research Analyst at Maxim Group

    Gabrielle Zhou is an Equity Research Analyst at Maxim Group, specializing in coverage of innovative growth companies across the technology, biotech, and healthcare sectors. She has provided investment research on firms like Ainos, Inc., Senti Biosciences, and PolarityTE, demonstrating a meticulous approach to identifying high-potential opportunities and generating actionable insights for institutional clients. Zhou began her equity research career in the early 2020s and joined Maxim Group to deepen her focus on emerging markets after experience with financial modeling and client analysis at boutique investment firms. She holds FINRA Series 7 and 63 licenses, underscoring her professional rigor and regulatory compliance in the capital markets.

    Gabrielle Zhou's questions to SBOT leadership

    Gabrielle Zhou's questions to SBOT leadership • Q2 2016

    Question

    Gabrielle Zhou of Maxim Group inquired about the commercial production forecast for KLH for the remainder of the year and beyond, as well as the progress of key partners like Neovacs in their use of KLH for active immunotherapies.

    Answer

    President and CEO Frank Oakes explained that while he could not offer specific forecasts, Stellar expects continued strong growth in demand for KLH, with production anticipated to move from gram to kilogram quantities in future years. Regarding partners, he pointed to Neovacs' public announcements about advancing their lupus trial into the United States as a positive indicator of progress.

    Ask Fintool Equity Research AI